SIRT1: Regulator of p53 Deacetylation

Genes and Cancer

Volumn 4, Issue 3-4, 2013, Pages 112-117

  Lee, James T ^a   Gu, Wei ^b  

^a PSYCHOGENICS INC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

acetylation; deacetylation; p53; SIRT1; tumorigenesis

Indexed keywords

ACTIVE REGULATOR OF SIRT1; CASEIN KINASE II; DIHYDROCOUMARIN; ENZYME ACTIVATOR; ENZYME INHIBITOR; EX 527; HISTONE ACETYLTRANSFERASE PCAF; INAUHZIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SALERMIDE; SIRTINOL; SIRTUIN 1; SIRTUIN 1 INHIBITOR; SIRTUIN 2; SPLITOMICIN; TENOVIN 1; TENOVIN 6; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; DEACETYLATION; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; SIRT1 GENE; TUMOR SUPPRESSOR GENE;

EID: 84887448528     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913484496     Document Type: Article

References (78)

1. Morris BJ.Seven sirtuins for seven deadly diseases of aging.Free Radic Biol Med. 2013;56:133-71.
2. Brooks CL,Gu W.How does SIRT1 affect metabolism, senescence and cancer?.Nat Rev Cancer. 2009;9 (2): 123-8.
3. Tanny JC,Dowd GJ,Huang J,Hilz H,Moazed D.An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing.Cell. 1999;99 (7): 735-45.
4. Hasty P.The impact energy metabolism and genome maintenance have on longevity and senescence: lessons from yeast to mammals.Mech Ageing Dev. 2001;122 (15): 1651-62.
5. Howitz KT,Bitterman KJ,Cohen HY,et al.Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.Nature. 2003;425 (6954): 191-6.
6. Wood JG,Rogina B,Lavu S,et al.Sirtuin activators mimic caloric restriction and delay ageing in metazoans.Nature. 2004;430 (7000): 686-9.
7. Beher D,Wu J,Cumine S,et al.Resveratrol is not a direct activator of SIRT1 enzyme activity.Chem Biol Drug Des. 2009;74 (6): 619-24.
8. Pacholec M,Bleasdale JE,Chrunyk B,et al.SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.J Biol Chem. 2010;285 (11): 8340-51.
9. Chen D,Bruno J,Easlon E,et al.Tissue-specific regulation of SIRT1 by calorie restriction.Genes Dev. 2008;22 (13): 1753-7.
10. Kwon HS,Ott M.The ups and downs of SIRT1.Trends Biochem Sci. 2008;33 (11): 517-25.
11. Nemoto S,Fergusson MM,Finkel T.Nutrient availability regulates SIRT1 through a forkhead-dependent pathway.Science. 2004;306 (5704): 2105-8.
12. Nisoli E,Tonello C,Cardile A,et al.Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS.Science. 2005;310 (5746): 314-7.
13. Das C,Lucia MS,Hansen KC,Tyler JK.CBP/p300-mediated acetylation of histone H3 on lysine 56.Nature. 2009;459 (7243): 113-7.
14. Vaquero A,Scher M,Lee D,et al.Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.Mol Cell. 2004;16 (1): 93-105.
15. Vaquero A,Sternglanz R,Reinberg D.NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.Oncogene. 2007;26 (37): 5505-20.
16. Yamagata K,Kitabayashi I.Sirt1 physically interacts with Tip60 and negatively regulates Tip60-mediated acetylation of H2AX.Biochem Biophys Res Commun. 2009;390 (4): 1355-60.
17. Luo J,Nikolaev AY,Imai S,et al.Negative control of p53 by Sir2alpha promotes cell survival under stress.Cell. 2001;107 (2): 137-48.
18. Vaziri H,Dessain SK,Ng Eaton E,et al.hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.Cell. 2001;107 (2): 149-59.
19. Motta MC,Divecha N,Lemieux M,et al.Mammalian SIRT1 represses forkhead transcription factors.Cell. 2004;116 (4): 551-63.
20. Nemoto S,Fergusson MM,Finkel T.SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}.J Biol Chem. 2005;280 (16): 16456-60.
21. Picard F,Kurtev M,Chung N,et al.Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.Nature. 2004;429 (6993): 771-6.
22. Byles V,Chmilewski LK,Wang J,et al.Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells.Int J Biol Sci. 2010;6 (6): 599-612.
23. Tanno M,Sakamoto J,Miura T,Shimamoto K,Horio Y.Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1.J Biol Chem. 2007;282 (9): 6823-32.
24. Gu W,Roeder RG.Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.Cell. 1997;90 (4): 595-606.
25. Dai C,Gu W.p53 post-translational modification: deregulated in tumorigenesis.Trends Mol Med. 2010;16 (11): 528-36.
26. Li M,Luo J,Brooks CL,Gu W.Acetylation of p53 inhibits its ubiquitination by Mdm2.J Biol Chem. 2002;277 (52): 50607-11.
27. Li M,Chen D,Shiloh A,et al.Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization.Nature. 2002;416 (6881): 648-53.
28. Liu L,Scolnick DM,Trievel RC,et al.p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.Mol Cell Biol. 1999;19 (2): 1202-9.
29. Di Stefano V,Soddu S,Sacchi A,D'Orazi G.HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.Oncogene. 2005;24 (35): 5431-42.
30. Sykes SM,Mellert HS,Holbert MA,et al.Acetylation of the p53 DNA-binding domain regulates apoptosis induction.Mol Cell. 2006;24 (6): 841-51.
31. Tang Y,Luo J,Zhang W,Gu W.Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis.Mol Cell. 2006;24 (6): 827-39.
32. Tang Y,Zhao W,Chen Y,Zhao Y,Gu W.Acetylation is indispensable for p53 activation.Cell. 2008;133 (4): 612-26.
33. Li T,Kon N,Jiang L,et al.Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence.Cell. 2012;149 (6): 1269-83.
34. Cheng HL,Mostoslavsky R,Saito S,et al.Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.Proc Natl Acad Sci U S A. 2003;100 (19): 10794-9.
35. Oberdoerffer P,Michan S,McVay M,et al.SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.Cell. 2008;135 (5): 907-18.
36. Kim EJ,Kho JH,Kang MR,Um SJ.Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity.Mol Cell. 2007;28 (2): 277-90.
37. Kim JE,Chen J,Lou Z.DBC1 is a negative regulator of SIRT1.Nature. 2008;451 (7178): 583-6.
38. Zhao W,Kruse JP,Tang Y,et al.Negative regulation of the deacetylase SIRT1 by DBC1.Nature. 2008;451 (7178): 587-90.
39. Menssen A,Hydbring P,Kapelle K,et al.The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.Proc Natl Acad Sci U S A. 2012;109 (4): E187-96.
40. Yamakuchi M,Ferlito M,Lowenstein CJ.miR-34a repression of SIRT1 regulates apoptosis.Proc Natl Acad Sci U S A. 2008;105 (36): 13421-6.
41. Li L,Yuan L,Luo J,et al.MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.Clin Exp Med. 2012;:24.
42. Flick F,Luscher B.Regulation of sirtuin function by posttranslational modifications.Front Pharmacol. 2012;3:29.
43. Sasaki T,Maier B,Koclega KD,et al.Phosphorylation regulates SIRT1 function.PLoS One. 2008;3 (12): e4020.
44. Zschoernig B,Mahlknecht U.Carboxy- terminal phosphorylation of SIRT1 by protein kinase CK2.Biochem Biophys Res Commun. 2009;381 (3): 372-7.
45. Kang H,Jung JW,Kim MK,Chung JH.CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage.PLoS One. 2009;4 (8): e6611.
46. Dixit D,Sharma V,Ghosh S,Mehta VS,Sen E.Inhibition of casein kinase-2 induces p53- dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition.Cell Death Dis. 2012;3 (2): e271.
47. Nasrin N,Kaushik VK,Fortier E,et al.JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.PLoS One. 2009;4 (12): e8414.
48. Lin Z,Yang H,Kong Q,et al.USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development.Mol Cell. 2012;46 (4): 484-94.
49. Yang Y,Fu W,Chen J,et al.SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress.Nat Cell Biol. 2007;9 (11): 1253-62.
50. Liu X,Wang D,Zhao Y,et al.Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1).Proc Natl Acad Sci U S A. 2011;108 (5): 1925-30.
51. Park SJ,Ahmad F,Philp A,et al.Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.Cell. 2012;148 (3): 421-33.
52. Canto C,Gerhart-Hines Z,Feige JN,et al.AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.Nature. 2009;458 (7241): 1056-60.
53. Price NL,Gomes AP,Ling AJ,et al.SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.Cell Metab. 2012;15 (5): 675-90.
54. Nin V,Escande C,Chini CC,et al.Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.J Biol Chem. 2012;287 (28): 23489-501.
55. Lee CW,Wong LL,Tse EY,et al.AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.Cancer Res. 2012;72 (17): 4394-404.
56. Alcain FJ,Villalba JM.Sirtuin activators.Expert Opin Ther Pat. 2009;19 (4): 403-14.
57. Villalba JM,de Cabo R,Alcain FJ.A patent review of sirtuin activators: an update.Expert Opin Ther Pat. 2012;22 (4): 355-67.
58. Camins A,Sureda FX,Junyent F,et al.Sirtuin activators: designing molecules to extend life span.Biochim Biophys Acta. 2010;1799 (10-12): 740-9.
59. Bitterman KJ,Anderson RM,Cohen HY,Latorre-Esteves M,Sinclair DA.Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.J Biol Chem. 2002;277 (47): 45099-107.
60. Denu JM.Vitamin B3 and sirtuin function.Trends Biochem Sci. 2005;30 (9): 479-83.
61. Audrito V,Vaisitti T,Rossi D,et al.Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.Cancer Res. 2011;71 (13): 4473-83.
62. Bedalov A,Gatbonton T,Irvine WP,Gottschling DE,Simon JA.Identification of a small molecule inhibitor of Sir2p.Proc Natl Acad Sci U S A. 2001;98 (26): 15113-8.
63. Grozinger CM,Chao ED,Blackwell HE,Moazed D,Schreiber SL.Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening.J Biol Chem. 2001;276 (42): 38837-43.
64. Ota H,Tokunaga E,Chang K,et al.Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.Oncogene. 2006;25 (2): 176-85.
65. Lara E,Mai A,Calvanese V,et al.Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect.Oncogene. 2009;28 (6): 781-91.
66. Pagans S,Pedal A,North BJ,et al.SIRT1 regulates HIV transcription via Tat deacetylation.PLoS Biol. 2005;3 (2): e41.
67. Heltweg B,Gatbonton T,Schuler AD,et al.Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.Cancer Res. 2006;66 (8): 4368-77.
68. Olaharski AJ,Rine J,Marshall BL,et al.The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases.PLoS Genet. 2005;1 (6): e77.
69. Napper AD,Hixon J,McDonagh T,et al.Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.J Med Chem. 2005;48 (25): 8045-54.
70. Solomon JM,Pasupuleti R,Xu L,et al.Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.Mol Cell Biol. 2006;26 (1): 28-38.
71. Zhang Q,Zeng SX,Zhang Y,et al.A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.EMBO Mol Med. 2012;4 (4): 298-312.
72. Zhang Y,Zhang Q,Zeng SX,Mayo LD,Lu H.Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.Cancer Biol Ther. 2012;13 (10): 915-24.
73. Lain S,Hollick JJ,Campbell J,et al.Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.Cancer Cell. 2008;13 (5): 454-63.
74. Li L,Wang L,Wang Z,et al.Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.Cancer Cell. 2012;21 (2): 266-81.
75. Tseng RC,Lee CC,Hsu HS,Tzao C,Wang YC.Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.Neoplasia. 2009;11 (8): 763-70.
76. Deng CX.SIRT1: is it a tumor promoter or tumor suppressor?.Int J Biol Sci. 2009;5 (2): 147-52.
77. Cho IR,Koh SS,Malilas W,et al.SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of beta-catenin.Biochem Biophys Res Commun. 2012;423 (2): 270-5.
78. Yuan J,Minter-Dykhouse K,Lou Z.A c-Myc-SIRT1 feedback loop regulates cell growth and transformation.J Cell Biol. 2009;185 (2): 203-11.